GP Oxan

Produkt Beschreibung

Meta Description:

UK clinical monograph on GP Oxan (oxandrolone) detailing molecular pharmacology, $17\alpha$-alkylation, clinical history, adverse effects, and Class C regulatory status.

1. Classification and Chemical Overview

GP Oxan is an unregulated commercial trade formulation representing an oral solid dosage preparation of the synthetic anabolic-androgenic steroid (AAS) oxandrolone (chemically designated as $17\beta\text{-hydroxy-17}\alpha\text{-methyl-2-oxa-5}\alpha\text{-androstan-3-one}$). Structurally, oxandrolone is a synthetic derivative of dihydrotestosterone (DHT) characterized by two fundamental molecular modifications: the substitution of the carbon-2 atom in the steroid A-ring with an oxygen atom (yielding a 2-oxa heterocyclic ring system) and alkylation at the carbon-17 position with a methyl group in the alpha orientation ($17\alpha\text{-alkylation}$). The 2-oxa ring substitution enhances biological stability and confers marked resistance to intracellular enzymatic deactivation by skeletal muscle $3\alpha\text{-hydroxysteroid dehydrogenase}$ ($3\alpha\text{-HSD}$), while the $17\alpha\text{-methyl}$ moiety provides steric hindrance against first-pass hepatic $17\beta\text{-hydroxysteroid}$ oxidation, ensuring high systemic bioavailability following oral administration. Finished preparations under the trade style GP Oxan typically present as oral tablets (commonly dosed at $10\text{ mg}$ oder $50\text{ mg}$) formulated alongside inert tableting excipients such as microcrystalline cellulose, lactose monohydrate, magnesium stearate, and croscarmellose sodium.

Within the United Kingdom regulatory framework, GP Oxan possesses no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). While oxandrolone as an active pharmaceutical ingredient has held licensed indications historically (and remains an authorized orphan medicinal product in specific foreign jurisdictions for severe catabolic wasting, severe burn injury convalescence, and Turner syndrome), preparations distributed under the trade brand “GP Oxan” operate entirely outside licensed pharmaceutical channels. Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, oxandrolone is categorized as a Class C, Schedule 4 (Part II) controlled drug. It is not catalogued in the British National Formulary (BNF) as an approved UK medicinal brand and is absent from standard NHS prescribing formularies. Formulations bearing the designation GP Oxan originate exclusively from underground laboratories (UGLs) and unregulated grey-market distributors, posing substantial clinical risks regarding dosage inaccuracies, active pharmaceutical ingredient (API) substitution, industrial chemical contaminants, and lack of good manufacturing practice (GMP) oversight.

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of GP Oxan involves direct intracellular androgen receptor activation, complete resistance to aromatisation, absence of $5\alpha$-reduction, and potent cellular anabolism:

• Androgen Receptor (AR) Agonism and Myofibrillar Protein Synthesis: Following gastrointestinal absorption, intact oxandrolone binds directly with high affinity to intracellular androgen receptors in skeletal myocytes, osteoblasts, and bone marrow stromal cells. The ligand-receptor complex undergoes conformational activation and translocates across the nuclear envelope into the nucleoplasm, where it binds to specific androgen response elements (AREs) on genomic DNA. This stimulates RNA polymerase II-directed transcription, significantly increasing amino acid uptake, intracellular nitrogen retention, and myofibrillar protein synthesis, while concurrently upregulating the expression of insulin-like growth factor-1 (IGF-1) in skeletal muscle tissue. Its anabolic-to-androgenic ratio is exceptionally high, estimated between $322:24$ und $630:24$ (relative to methyltestosterone at $100:100$).

• Complete Absence of Aromatase Conversion: Due to its fully saturated $5\alpha$-reduced steroid nucleus and the presence of the 2-oxa substitution, oxandrolone cannot serve as a substrate for the cytochrome P450 aromatase enzyme complex ($CYP19A1$). Consequently, it undergoes zero bioconversion into oestrogens ($17\beta\text{-oestradiol}$), eliminating risks of direct oestrogen-mediated fluid retention, hypertension via hyperoestrogenism, or true oestrogenic gynaecomastia.

• Lack of Peripheral $5\alpha\text{-Reductase}$ Amplification: Because the A/B ring junction is already saturated in the $5\alpha\text{-configuration}$, oxandrolone does not interact with or undergo metabolic amplification by $5\alpha\text{-reductase}$ isoenzymes (types 1, 2, or 3) into a more potent androgenic metabolite within androgen-sensitive peripheral target tissues (such as the scalp, prostate gland, and sebaceous units). Its peripheral tissue effects are mediated directly by the parent compound.

• Anticatabolic Glucocorticoid Antagonism: Oxandrolone exhibits antagonistic affinity for intracellular glucocorticoid receptors (GRs), competitively displacing endogenous cortisol in skeletal muscle tissue. This attenuates ubiquitin-proteasome pathway degradation of myofibrillar contractile proteins, promoting profound preservation of lean body mass during states of acute physiological stress, prolonged immobilization, or severe caloric deprivation.

• Hypothalamic-Pituitary-Gonadal (HPG) Axis Suppression: Although frequently mischaracterized in consumer communities as a “mild” steroid that does not suppress endogenous hormones, oxandrolone exerts direct negative feedback inhibition at the hypothalamic arcuate nucleus and anterior pituitary gonadotrophs. Supraphysiological systemic concentrations suppress the pulsatile secretion of gonadotropin-releasing hormone (GnRH), luteinising hormone (LH), and follicle-stimulating hormone (FSH), leading to secondary downregulation of endogenous testicular testosterone synthesis.

3. Approved UK Clinical Indications and Therapeutic Scope

GP Oxan possesses no approved clinical indications in the United Kingdom. No randomized, double-blind, multicentre Phase I–III clinical trials conforming to MHRA statutory criteria have been conducted to evaluate this specific unlicensed brand for therapeutic safety, dosage precision, or clinical efficacy.

The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate GP Oxan into any clinical management pathway. It is absent from clinical guidelines governing severe burns care, chronic obstructive pulmonary disease, chronic kidney disease wasting, or paediatric growth disorders. In authorized international jurisdictions, pharmaceutical-grade oxandrolone has been licensed for:

• Adjunctive catabolic reversal and lean mass restoration following extensive severe thermal injury (burns), major surgical trauma, or chronic systemic infections.

• Counteracting glucocorticoid-induced protein catabolism during prolonged systemic corticosteroid therapy.

• Promoting linear skeletal growth in paediatric female patients with confirmed Turner syndrome (concomitant with recombinant human growth hormone).

• Palliative treatment of severe muscle wasting and cachexia secondary to advanced human immunodeficiency virus (HIV) infection.

The practical application of GP Oxan is confined entirely to illicit athletic performance enhancement, competitive bodybuilding, and forensic doping toxicology. In these unapproved settings, it is sought for:

• Accrual of lean skeletal muscle mass with minimal fluid accumulation during pre-competition phases (“cutting”).

• Augmentation of neuromuscular strength-to-weight ratios in weight-class-restricted athletic disciplines.

• Enhanced muscular recovery velocity between intense athletic conditioning bouts.

GP Oxan holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never be substituted for licensed testosterone replacement therapy (TRT).

4. Pharmacokinetic Profile and Metabolic Fate

Because GP Oxan is formulated as an oral solid tablet, its pharmacokinetic disposition is determined by rapid intestinal uptake, hepatic stability, and primarily renal elimination:

• Absorption: Oxandrolone exhibits high oral bioavailability ($>95\%$) owing to its lipophilicity and structural $17\alpha\text{-alkylation}$, which protects the molecule from extensive presystemic intestinal and first-pass hepatic degradation. Peak plasma concentrations ($C_{max}$) are typically achieved between 1 and 2 hours following oral ingestion in a fasted state, although concurrent ingestion of high-fat meals may moderately prolong $T_{max}$.

• Distribution: Once absorbed into systemic circulation, oxandrolone binds extensively to plasma proteins, exhibiting an estimated binding fraction of $94\text{ to }97\%$, predominantly to human serum albumin with weak, non-specific binding to sex hormone-binding globulin (SHBG). Its low affinity for SHBG causes competitive displacement of endogenous steroids, transiently elevating free circulating fractions of other hormones. It possesses an apparent volume of distribution ($V_d$) ranging from $0.5\text{ to }0.8\text{ L/kg}$, penetrating skeletal muscle, hepatic parenchyma, adipose tissue, and crossing the blood-brain barrier.

• Biotransformation: Unlike most natural and esterified anabolic-androgenic steroids that undergo extensive hepatic Phase I oxidation and rapid Phase II conjugation, oxandrolone is uniquely resistant to hepatic microsomal transformation. Its biotransformation does not rely on the cytochrome P450 monooxygenase system to a significant degree. A substantial portion of an oral dose bypasses hepatic metabolism entirely; the fraction that is metabolized undergoes slow hepatic epimerisation, hydroxylation, and conjugation into inactive polar metabolites, primarily $17\alpha\text{-oxandrolone}$ and 16-hydroxyoxandrolone.

• Elimination: Systemic elimination occurs predominantly via the renal system. Uniquely among $17\alpha\text{-alkylated}$ steroids, approximately $25\text{ to }40\%$ of an administered oral dose of oxandrolone is excreted in the urine as intact, unchanged active drug. The remainder is eliminated in the urine as polar glucuronide and sulfate conjugates, with less than $3\text{ to }5\%$ cleared via biliary secretion into faeces. The elimination half-life ($t_{1/2}$) in healthy human adults is relatively short, ranging between 9 and 12 hours (extending up to 13 hours in elderly cohorts). Trace urinary metabolites remain detectable via gas chromatography-mass spectrometry (GC-MS) or LC-MS/MS anti-doping screens for several weeks to months following complete discontinuation.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect reported in athletic and non-medical contexts is a moderate increase in lean skeletal muscle mass and muscular strength accompanied by a dry, vascular aesthetic devoid of subcutaneous fluid retention. However, its orally bioavailable, $17\alpha\text{-alkylated}$ chemical structure presents serious multi-system adverse effects:

• Cardiovascular and Lipid Toxicity:

  • Severe atherogenic dyslipidaemia: oral $17\alpha\text{-alkylated}$ steroids exert profound, direct hepatic lipase induction. Oxandrolone administration causes drastic reductions in high-density lipoprotein cholesterol (HDL-C; routinely dropping by $50\text{ to }80\%$, often falling below $0.3\text{ mmol/L}$) and marked elevations in low-density lipoprotein cholesterol (LDL-C; rising by $30\text{ to }60\%$), dramatically accelerating coronary artery atherosclerosis and endothelial vascular disease.

  • Systemic hypertension: secondary to vascular endothelial dysfunction, heightened vascular tone, and alterations in renal vascular resistance.

  • Subclinical myocardial remodeling: chronic exposure promotes pathological left ventricular concentric hypertrophy, microvascular ischaemia, and impaired myocardial relaxation.

  • Polycythaemia: stimulation of renal erythropoietin production elevates haematocrit ($>52\%$), increasing blood viscosity and thrombotic risk (stroke, pulmonary embolism, myocardial infarction).

• Hepatic Toxicity (Hepatotoxicity):

  • Because it is a $17\alpha\text{-alkylated}$ oral compound, oxandrolone places metabolic strain on hepatic parenchymal and biliary architecture. Although considered less hepatotoxic than methyltestosterone or stanozolol on a milligram-for-milligram basis, chronic administration can cause significant elevations in serum transaminases (ALT, AST) and gamma-glutamyl transferase (GGT).

  • Prolonged or high-dose exposure carries recognized risks of chronic intrahepatic cholestasis, peliosis hepatis (blood-filled cystic lesions in the liver parenchyma), hepatic adenomas, and, rarely, malignant hepatocellular carcinoma.

• Endocrine and Gonadal Axis Suppression:

  • Marked suppression of the HPG axis: negative feedback at the hypothalamus and pituitary downregulates LH and FSH secretion, resulting in testicular atrophy, azoospermia, and prolonged secondary hypogonadotrophic hypogonadism following drug withdrawal.

• Androgenic and Dermatological Effects:

  • Androgenic dermatopathy: although exhibiting a low androgenic rating, high-dose administration frequently triggers severe cystic acne (predominantly localized to the shoulders, upper back, and face) and accelerates androgenetic alopecia in genetically predisposed individuals.

  • Virilisation in Females: When taken by females at doses exceeding clinical paediatric thresholds, oxandrolone causes irreversible virilising signs, including deepening of the vocal cords, clitoromegaly, severe hirsutism, facial hair growth, and chronic amenorrhoea.

• Renal and Metabolic Strain:

  • Elevated serum creatinine levels: secondary to both direct inhibition of creatinine breakdown/alterations in tubular handling and accelerated skeletal muscle turnover, which can confound laboratory assessment of estimated glomerular filtration rate (eGFR).

6. Contraindications, Drug Interactions, and Clinical Precautions

Given its non-approved clinical status, oral hepatotoxic structure, and marked atherogenic profile, GP Oxan requires strict adherence to pharmacological contraindications and clinical harm-minimisation standards:

• Contraindications:

  • Absolute Contraindication in All Humans: The preparation is an illicit, unregulated chemical tablet lacking medicinal safety clearance.

  • Known or Suspected Malignancy: Absolute contraindication in prostate adenocarcinoma, male breast carcinoma, or any hormone-sensitive neoplasm; absolute contraindication in known or suspected active hepatic neoplasms.

  • Pre-existing Cardiovascular Disease: Absolute contraindication in severe coronary artery disease, history of myocardial infarction, cerebrovascular disease (stroke/TIA), uncontrolled hypertension, or chronic heart failure.

  • Significant Hepatic Impairment: Absolute contraindication in patients with baseline liver cirrhosis, active viral or autoimmune hepatitis, cholestatic liver disease, or baseline transaminases exceeding three times the upper limit of normal (ULN).

  • Severe Renal Impairment: Contraindicated in chronic kidney disease (CKD Stages 4–5) due to predominantly renal excretion of the active parent molecule.

  • Pregnancy and Lactation: Absolute contraindication; severe teratogenicity, fatal fetal harm, and profound irreversible masculinisation/virilisation of the female fetus.

  • Paediatric Population: Contraindicated in children and adolescents outside licensed, specialist-supervised paediatric orphan indications due to premature epiphyseal plate closure, stunting of adult stature, and precocious sexual development.

• Drug Interactions:

  • Oral Anticoagulants (e.g., Warfarin, DOACs): Oxandrolone significantly enhances patient sensitivity to oral anticoagulants by inhibiting hepatic clearance of warfarin and altering prothrombin complex synthesis. Severe, unpredictable elevations in the International Normalised Ratio (INR) and life-threatening haemorrhagic events can occur, requiring extreme clinical vigilance and substantial warfarin dose reductions.

  • Oral Hypoglycaemic Agents and Insulin: Anabolic steroids alter peripheral carbohydrate tolerance and increase insulin sensitivity; co-administration with metformin, sulfonylureas, or exogenous insulin can precipitate severe, unpredictable hypoglycaemic episodes, requiring close blood glucose monitoring.

  • Hepatotoxic Medications (e.g., Paracetamol, Methotrexate, Statins, Azole Antifungals): Concurrent use with other hepatotoxic substances exerts additive cytotoxic stress on hepatocytes, multiplying risks of severe drug-induced liver injury (DILI).

  • Other Anabolic-Androgenic Steroids: Stacking with other oral $17\alpha\text{-alkylated}$ steroids compounds hepatic parenchymal damage and accelerates severe lipid dysregulation.

• Clinical Precautions and Harm Minimisation:

  • Cardiovascular Alarm Symptoms (“Red Flags”): Patients presenting with crushing central chest pressure, acute exertional dyspnoea, sudden unilateral focal neurological deficits (facial droop, speech impairment), or acute unilateral lower limb swelling require immediate emergency (999/A&E) transfer.

  • Hepatic Alarm Signs: Emergence of clinical scleral or cutaneous jaundice, dark brown urine, pale acholic stools, persistent right upper quadrant pain, or intractable pruritus indicates acute cholestasis or severe hepatic injury, necessitating immediate drug cessation and urgent specialist hepatological admission.

  • Structured Diagnostic Workup for Illicit AAS Users: Clinicians encountering individuals actively using or discontinuing GP Oxan should perform a comprehensive risk assessment: 12-lead ECG, blood pressure evaluation, full blood count (monitoring haematocrit), comprehensive lipid profile (total cholesterol, HDL-C, LDL-C, triglycerides), liver function tests (ALT, AST, ALP, GGT, bilirubin), renal function tests (urea, creatinine, eGFR, cystatin-C), and an early-morning endocrine panel (total testosterone, SHBG, LH, FSH, oestradiol).

  • Clinical Cessation Support: Clinicians should counsel patients directly and objectively on the systemic toxicities of unregulated UGL oral steroids, support structured drug cessation, and coordinate endocrine referral for the diagnosis and management of prolonged post-AAS hypogonadotrophic hypogonadism where clinically indicated.